Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles

V.K.V. American Hospital, Istanbul

Status and phase: Terminated; Phase 3

Conditions: Infertility

Treatments: Drug: triptorelin acetate; Drug: NaCl %0.9

Study type: Interventional

Funder types: Other

Identifiers

NCT01007851

AH-48/07

Details and patient eligibility

About

GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

Sex: Female

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.
• Embryo transfer performed on day 3

Exclusion criteria

• Participation in another trial that was being conducted in our unit at the same time.
• Preimplantation genetic screening cycles.
• Day 5 embryo transfers.

Trial design

0 participants in 2 patient groups, including a placebo group

GnRH agonist

Experimental group

Treatment:

Drug: triptorelin acetate

Saline

Placebo Comparator group

Treatment:

Drug: NaCl %0.9